Advertisement

Evidence-Based Pharmacotherapy of Chronic Pain

  • Sukdeb Datta
  • Laxmaiah Manchikanti
Chapter

Abstract

Pharmacotherapy for chronic pain remains very much an art. Pharmacologic approaches are generally combined with other approaches to the treatment of chronic pain including physical medicine, behavioral medicine, neuromodulation, and interventional, surgical, and complementary and alternative medicine approaches.

Pharmacotherapy of chronic pain includes acetaminophen, traditional nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), COX-2 selective inhibitors, tramadol, opioids (e.g., morphine, hydrocodone/acetaminophen, oxycodone, hydromorphone, fentanyl, oxymorphone, buprenorphine, methadone, tapentadol), calcium channel alpha-2 delta ligands, skeletal relaxants (baclofen, tizanidine, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine), topical analgesics (lidocaine 5% patch, capsaicin/high-concentration capsaicin patch, topical NSAIDs), and botulinum toxins.

References

  1. Adams, E. H., Breiner, S., Cicero, T. J., et al. (2006). A comparison of abuse liability of tramadol, NSAIDs and hydrocodone in patients with chronic pain. Journal of Pain and Symptom Management, 31, 465–476.Google Scholar
  2. Arnold, L. M., Goldenberg, D. L., Stanford, S. B., et al. (2007). Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis and Rheumatism, 56, 1336–1344.PubMedCrossRefGoogle Scholar
  3. Arnold, L. M., Keck, P. E., Jr., & Welge, J. A. (2000). Antidepressant treatment of fibromyalgia. A metaanalysis and review. Psychosomatics, 41, 104–113.PubMedCrossRefGoogle Scholar
  4. Backonja, M. M., Malan, T. P., Vanhove, G. F., et al. (2010). NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomized, double-blind, controlled study with an open-label extension. Pain Medicine, 11, 600–608.PubMedCrossRefGoogle Scholar
  5. Backonja, M. M., Wallace, M. S., Blonsky, E. R., et al. (2008). NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: A randomized, double-blind, controlled study. Lancet Neurology, 7, 1106–1112.PubMedCrossRefGoogle Scholar
  6. Baraf, H. S., Gloth, F. M., Barthel, H. R., et al. (2011). Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: Pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials. Drugs & Aging, 28, 27–40.CrossRefGoogle Scholar
  7. Barden, J., Derry, S., McQuay, H. J., et al. (2009). Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database Systemic Reviews, (4), CD007355.Google Scholar
  8. Bennett, R. M., Kamin, M., Karim, R., et al. (2003). Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. The American Journal of Medicine, 114, 537–545.PubMedCrossRefGoogle Scholar
  9. Bockbrader, H. N., Wesche, D., Miller, R., et al. (2010). A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clinical Pharmacokinetics, 49, 661–669.PubMedCrossRefGoogle Scholar
  10. Butler, S. F., Budman, S. H., Fernandez, K., et al. (2007). Development and validation of the Current Opioid Misuse Measure. Pain, 130, 114–156.CrossRefGoogle Scholar
  11. Butler, S. F., Fernandez, K., Benoit, C., et al. (2008). Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). The Journal of Pain, 9(4), 360–372.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Carey, E. T., & Sawsan, A.-S. (2016). New developments in the pharmacotherapy of neuropathic pelvic pain. Future Sci. OA, 2(4), FS0148.CrossRefGoogle Scholar
  13. Case, J. P., Baliunas, A. J., & Black, J. A. (2003). Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: A randomized, double-blind, placebo controlled comparison trial with diclofenac sodium. Archives of Internal Medicine, 163, 169e78.Google Scholar
  14. Cheong, Y. C., Smotra, G., & Williams, A. C. (2014). Non-surgical interventions for the management of chronic pelvic pain. Cochrane Database Systemic Reviews, (3), CD008797.Google Scholar
  15. Chou, R., Peterson, K., & Helfand, M. (2004). Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. Journal of Pain and Symptom Management, 28, 140–175.PubMedCrossRefGoogle Scholar
  16. Christo, P. J., Manchikanti, L., Ruan, X., et al. (2011). Urine drug testing in chronic pain. Pain Physician, 14, 123–143.PubMedGoogle Scholar
  17. Cone, E. J., Heit, H. A., Caplan, Y. H., et al. (2006). Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. Journal of Analytical Toxicology, 30, 1–5.PubMedCrossRefGoogle Scholar
  18. Dart, R. C., & Bailey, E. (2007). Does therapeutic use of acetaminophen cause acute liver failure? Pharmacotherapy, 27, 1219–1230.PubMedCrossRefGoogle Scholar
  19. Davies, P. S., & Galer, B. S. (2004). Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs, 64, 937–947.PubMedCrossRefGoogle Scholar
  20. Deer, T., Krames, E. S., Hassenbusch, S. J., et al. (2007). Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: Report of an interdisciplinary expert panel. Neuromodulation, 10, 300–328.PubMedCrossRefGoogle Scholar
  21. Derry, S., Lloyd, R., Moore, R. A., et al. (2009). Topical capsaicin for chronic neuropathic pain in adults. Cochrane Database Systemic Reviews, (4), CD007393.Google Scholar
  22. Deshpande, A., Furlan, A., Mailis-Gagnon, A., et al. (2007). Opioids for chronic low-back pain. Cochrane Database Systemic Reviews, (3), CD004959.Google Scholar
  23. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain- United States, 2016. JAMA, 315, 1624–1645.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Dutta, A., McKie, S., & Deakin, J. F. W. (2015). Ketamine and other potential glutamate antidepressants. Psychiatry Res, Jan 30; 225 (1–2).PubMedCrossRefGoogle Scholar
  25. Dwight, M. M., Arnold, L. M., O’Brien, H., et al. (1998). An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics, 39, 14–17.PubMedCrossRefGoogle Scholar
  26. Dworkin, R. H., O’Connor, A. B., Backonja, M., et al. (2007). Pharmacologic management of neuropathic pain: Evidence based recommendation. Pain, 132, 237–251.PubMedCrossRefGoogle Scholar
  27. Eisenberg, E., McNicol, E. D., & Carr, D. B. (2005). Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin. Systematic review and meta-analysis trials. Journal of American Medical Association, 293, 3043–3052.CrossRefGoogle Scholar
  28. Fine, P. G., & Portenoy, R. K. (2007). Initiating and optimizing opioid therapy. In P. Fine (Ed.), A clinical guide to opioid analgesia. New York: Vendome Group, LLC.Google Scholar
  29. Finnerup, N. B., & Jensen, T. S. (2007). Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatric Disease and Treatment, 3, 885–891.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Finnerup, N. B., Otto, M., Jensen, T. S., et al. (2007). An evidence-based algorithm for the treatment of neuropathic pain. MedGenMed, 9, 36.PubMedPubMedCentralGoogle Scholar
  31. Finnerup, N. B., Otto, M., McQuay, H. J., et al. (2005). Algorithm for neuropathic pain treatment: An evidence based proposal. Pain, 118, 289–305.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Finnerup, N. B., Sindrup, S. H., & Jensen, T. S. (2010). The evidence for pharmacological treatment of neuropathic pain. Pain, 150, 573–581.PubMedCrossRefGoogle Scholar
  33. Fishman, S. M., Mahajan, G., Jung, S. W., et al. (2002). The trilateral opioid contract. Bridging the pain clinic and the primary care physician through the opioid contract. Journal of Pain and Symptom Management, 24, 335–344.PubMedCrossRefGoogle Scholar
  34. Furlan, A. D., Sandoval, J. A., Mailis-Gagnon, A., et al. (2006). Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. Canadian Medical Association Journal, 174, 1589–1594.PubMedCrossRefGoogle Scholar
  35. Galer, B. S., Rowbotham, M., Perander, J., et al. (2000). Topical diclofenac patch relieves minor sports injury pain: Results of a multicenter controlled clinical trial. Journal of Pain and Symptom Management, 19, 287–294.PubMedCrossRefGoogle Scholar
  36. Garcia Roderiguez, L. A., & Hernandez-Diaz, S. (2001). Risk of upper gastrointestinal complications among users of acetaminophen and non-steroidal anti-inflammatory drugs. Epidemiology, 12, 570e6.Google Scholar
  37. Gourlay, D., & Heit, H. A. (2006). Universal precautions: A matter of mutual trust and responsibility. Pain Medicine, 7, 210–211.PubMedCrossRefGoogle Scholar
  38. Gourlay, D. L., & Heit, H. A. (2005). Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Medicine, 6, 107–112.CrossRefGoogle Scholar
  39. Häuser, W., Bernardy, K., Uçeyler, N., et al. (2009). Treatment of fibromyalgia syndrome with antidepressants: A meta-analysis. Journal of American Medical Association, 301, 198–209.CrossRefGoogle Scholar
  40. Häuser, W., Petzke, F., Üçeyler, N., et al. (2011). Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: A systematic review with meta-analysis. Rheumatology (Oxford, England), 50, 532–543.CrossRefGoogle Scholar
  41. Heard, K., Green, J. L., Bailey, J. E., et al. (2007). A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Alimentary Pharmacology & Therapeutics, 26, 283–290.CrossRefGoogle Scholar
  42. Heit, H. A., & Gourlay, D. L. (2004). Urine drug testing in pain medicine. Journal of Pain and Symptom Management, 27, 260–267.PubMedCrossRefGoogle Scholar
  43. Irving, G. A., Backonja, M. M., Dunteman, E., et al. (2011). A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Medicine, 12, 99–109.PubMedCrossRefGoogle Scholar
  44. Jalan, R., Williams, R., & Bernuau, J. (2006). Paracetamol: Are therapeutic doses entirely safe? The Lancet, 368, 2195–2196.CrossRefGoogle Scholar
  45. Jirarattanaphochai, K., & Jung, S. (2008). Nonsteroidal antiinflammatory drugs for postoperative pain management after lumbar spine surgery: A meta-analysis of randomized controlled trials. Journal of Neurosurgery. Spine, 9, 22–31.PubMedCrossRefGoogle Scholar
  46. Joint Commission on the Accreditation of Healthcare Organizations. (1999). Patient rights and organization ethics. Referenced from the comprehensive accreditation manual for hospitals, update 3, 1999. Walter Reed Army Medical Center Web site. Retrieved July 5, 2007, from http://www.wramc.army.mil/JCAHO/Division.cfm?D_Id+1
  47. Joint statement from 21 health organizations and the Drug Enforcement Administration. Promoting pain relief and preventing abuse of pain medications: A critical balancing act. Biomedical Computing Group, University of Wisconsin Medical School Web site. Retrieved August 4, 2004., from http://www.medsch.wisc.edu/painpolicy/Consensus2.pdf
  48. Jones, P., & Lamdin, R. (2010). Oral cyclo-oxygenase 2 inhibitors versus other oral analgesics for acute soft tissue injury: Systematic review and meta-analysis. Clinical Drug Investigation, 30, 419–437.PubMedCrossRefGoogle Scholar
  49. Jones, V. W., Moore, K. A., & Peterson, D. M. (2011). Capsaicin 8% topical patch (qutenza) – a review of the evidence. Journal of Pain & Palliative Care Pharmacotherapy, 25, 32–41.CrossRefGoogle Scholar
  50. Jordan, K. M., Arden, N. K., Doherty, M., et al. (2003). EULAR recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases, 62, 1145e55.CrossRefGoogle Scholar
  51. Kalso, E., Edwards, J. E., Moore, R. A., et al. (2004). Opioids in chronic non-cancer pain: A systematic review of efficacy and safety. Pain, 112, 372–380.PubMedCrossRefGoogle Scholar
  52. Katz, N. (2002). The impact of pain management on quality of life. Journal of Pain and Symptom Management, 24, S38–S47.PubMedCrossRefGoogle Scholar
  53. Katz, N., & Fanciullo, G. (2002). Role of urine toxicology testing in the management of chronic opioid therapy. The Clinical Journal of Pain, 18, 576–582.CrossRefGoogle Scholar
  54. Kearney, P. M., Baigent, C., Godwin, J., et al. (2006). Do selective cyclo-oxygenase inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. British Medical Journal, 332, 1302e8.CrossRefGoogle Scholar
  55. Khaliq, W., Alam, S., & Puri, N. (2007). Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Systemic Reviews, 18(2), CD004846.Google Scholar
  56. Kim, D. W., Lee, S. K., & Ahnn, J. (2015). Botulinum toxin as a pain killer: players and actions in antinociception. Toxins (Basel), 7(7), 2435–2453.CrossRefGoogle Scholar
  57. Kuehl, K. S. (2010). Review of the efficacy and tolerability of the diclofenac epolamine topical patch 1.3% in patients with acute pain due to soft tissue injuries. Clinical Therapeutics, 32, 1001–1014.PubMedCrossRefGoogle Scholar
  58. Kuijpers, T., van Middelkoop, M., Rubinstein, S. M., et al. (2011). A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. European Spine Journal, 20, 40–50.PubMedCrossRefGoogle Scholar
  59. Larson, A. M., Polson, J., Fontana, R. J., et al. (2005). Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology, 42, 1364–1372.PubMedCrossRefGoogle Scholar
  60. Lee, S. S., Sphn, Y. W., Yoo, E. S., et al. (1991). Neurotoxicity and long lasting analgesia induced by capsaicinoids. The Journal of Toxicological Sciences, 16, 3–20.PubMedCrossRefGoogle Scholar
  61. Manchikanti, L., Kaye, A. M., Knezevic, N. N., et al. (2017). Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. Feb, 20(2S), S3–S92.Google Scholar
  62. Marjoribanks, J., Proctor, M., Farquhar, C., et al. (2010). Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Systemic Reviews, 20(1), CD001751.Google Scholar
  63. Mason, L., Moore, R. A., Derry, S., et al. (2004a). Systematic review of topical capsaicin for the treatment of chronic pain. British Medical Journal, 328, 991–994.PubMedCrossRefGoogle Scholar
  64. Mason, L., Moore, R. A., Edwards, J. E., et al. (2004b). Systematic review of efficacy of topical rubefacients containing salicylates for the treatment of acute and chronic pain. British Medical Journal, 328, 995–997.PubMedCrossRefGoogle Scholar
  65. Massey, T., Derry, S., Moore, R. A., et al. (2010). Topical NSAIDs for acute pain in adults. Cochrane Database Systemic Reviews, 16(6), CD007402.Google Scholar
  66. Max, M. B., Payne, R., Edwards, W. T., et al. (1999). Principles of analgesic use in the treatment of acute pain and cancer pain (4th ed.). Glenview: American Pain Society.Google Scholar
  67. McCarberg, B., & Cole, B. (2013). Pain in the older person. In R. J. Moore (Ed.), Handbook of pain and palliative care: Biobehavioral approaches for the life course. New York: Springer.Google Scholar
  68. McDiarmid, T., & Mackler, L. (2005). What is the addiction risk associated with tramadol? The Journal of Family Practice, 54, 72–73.PubMedGoogle Scholar
  69. McNicol, E., Horowicz-Mehler, N., Risk, R., et al. (2003). Management of opioid side effects in cancer related and chronic noncancer pain: A systematic review. The Journal of Pain, 4, 231–256.PubMedCrossRefGoogle Scholar
  70. Mercadante, S., & Bruera, E. (2006). Opioid switching: A systematic and critical review. Cancer Treatment Reviews, 32, 304–315.PubMedCrossRefGoogle Scholar
  71. Moore, R. A., Straube, S., Wiffen, P. J., et al. (2009). Pregabalin for acute and chronic pain in adults. Cochrane Database Systemic Reviews, 8(3), CD007076.Google Scholar
  72. Moore, R. A., Wiffen, P. J., Derry, S., et al. (2011). Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Systemic Reviews, 16(3), CD007938.Google Scholar
  73. Moulin, D., Boulanger, A., Clark, A. J., et al. (2014). Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag., 19(6), 328–335.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Nauta, M., Landsmeer, M. L., & Koren, G. (2009). Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: A systematic review of randomized trials. The American Journal of Surgery, 198, 256–261.PubMedCrossRefGoogle Scholar
  75. Nishishinya, B., Urrútia, G., Walitt, B., et al. (2008). Amitriptyline in the treatment of fibromyalgia: A systematic review of its efficacy. Rheumatology (Oxford, England), 47, 1741–1746.CrossRefGoogle Scholar
  76. Noble, M., Treadwell, J. R., Tregear, S. J., et al. (2010). Long-term opioid management for chronic noncancer pain. Cochrane Database Systemic Reviews, (1), CD006605.Google Scholar
  77. Noto, C., Pappagallo, M., & Szallasi, A. (2009). NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Current Opinion in Investigational Drugs, 10, 702–710.PubMedGoogle Scholar
  78. Nuesch, E., Rutjes, A. W., Husni, E., et al. (2009). Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Systemic Reviews, (4), CD003115.Google Scholar
  79. O’Malley, P. G., Balden, E., Tomkins, G., Santoro, J., Kroenke, K., & Jackson, J. L. (2000). Treatment of fibromyalgia with antidepressants: A meta-analysis. Journal of General Internal Medicine, 15(9), 659–666.PubMedPubMedCentralCrossRefGoogle Scholar
  80. Ottani, A., Leone, S., Sandrini, M., et al. (2006). The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors. European Journal of Pharmacology, 531, 280–281.PubMedCrossRefGoogle Scholar
  81. Oyler, J. M., Cone, E. J., Joseph, R. E., Jr., et al. (2000). Identification of hydrocodone in human urine following controlled codeine administration. Journal of Analytical Toxicology, 24, 530–535.PubMedCrossRefGoogle Scholar
  82. Passik, S. D., & Weinreb, H. I. (2000). Managing chronic nonmalignant pain: Overcoming obstacles to the use of opioids. Advances in Therapy, 17, 70–80.PubMedCrossRefGoogle Scholar
  83. Pesce, A., West, C., Rosenthal, M., et al. (2011). Illicit drug use in the pain patient population decreases with continued drug testing. Pain Physician, 14, 189–193.PubMedGoogle Scholar
  84. Quigley, C. (2004). Opioid switching to improve pain relief and drug tolerability. Cochrane Database Systemic Reviews, 3, CD004847.Google Scholar
  85. Rabbie, R., Derry, S., Moore, R. A., et al. (2010). Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Systemic Reviews, (10), CD008039.Google Scholar
  86. Raffa, R. B., & Stone, D. J., Jr. (2008). Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. The Journal of Pharmacology and Experimental Therapeutics, 325, 500–506.Google Scholar
  87. Rahme, E., Pettitt, D., & LeLorier, J. (2002). Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal anti-inflammatory drugs in an elderly population. Arthritis and Rheumatism, 46, 3046e54.CrossRefGoogle Scholar
  88. Ranoux, D., Attal, N., Morain, F., et al. (2008). Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Annals of Neurology, 64, 274–283.PubMedCrossRefGoogle Scholar
  89. Raskin, J., Smith, T. R., Wong, K., et al. (2006). Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. Journal of Palliative Medicine, 9, 29–40.PubMedCrossRefGoogle Scholar
  90. Roelofs, P. D., Deyo, R. A., Koes, B. W., et al. (2008). Nonsteroidal anti-inflammatory drugs for low back pain: An updated Cochrane review. Spine, 33, 1766–1774.PubMedCrossRefGoogle Scholar
  91. Rowbotham, M. C., Twilling, L., Davies, P. S., et al. (2003). Oral opioid therapy for chronic peripheral and central neuropathic pain. The New England Journal of Medicine, 348, 1223–1232.PubMedCrossRefGoogle Scholar
  92. Russell, I. J., Kamin, M., Bennett, R. M., et al. (2000). Efficacy of tramadol in treatment of pain in fibromyalgia. Journal of Clinical Rheumatology, 6, 250–257.PubMedCrossRefGoogle Scholar
  93. Saarto, T., & Wiffen, P. J. (2007). Antidepressants for neuropathic pain. Cochrane Database Systemic Reviews, 17(4), CD005454.Google Scholar
  94. Sansone, R. A., & Sansone, L. A. (2009). Tramadol: Seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont), 6, 17–21.Google Scholar
  95. Simpson, D. M., Brown, S., Tobias, J., et al. (2008). Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology, 70, 2305–2313.PubMedCrossRefGoogle Scholar
  96. Simpson, D. M., Gazda, S., Brown, S., et al. (2010). Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. Journal of Pain and Symptom Management, 39, 1053–1064.PubMedCrossRefGoogle Scholar
  97. Sindrup, S. H., Otto, M., Finnerup, N. B., et al. (2005). Antidepressants in the treatment of neuropathic pain. Basic & Clinical Pharmacology & Toxicology, 96, 399–409.CrossRefGoogle Scholar
  98. Skljarevski, V., Zhang, S., Desaiah, D., et al. (2010). Duloxetine versus placebo in patients with chronic low back pain: A 12-week, fixed-dose, randomized, double-blind trial. The Journal of Pain, 11, 1282–1290.PubMedCrossRefGoogle Scholar
  99. Smith, H. S. (2006). Goal-directed therapy agreements. Journal of Cancer Pain & Symptom Palliation, 1, 11–13.CrossRefGoogle Scholar
  100. Smith, H. S. (2007). Antidepressants: Classifications and implications for pain modulation. In Presented at the capital district pain research conference, Albany, NY.Google Scholar
  101. Smith, H. S. (2008). Pre-opioid prescribing period. In H. S. Smith (Ed.), Opioid therapy in the 21st century. New York: Oxford University Press.Google Scholar
  102. Smith, H. S. (2009). Potential analgesic mechanisms of acetaminophen. Pain Physician, 12, 269–280.PubMedGoogle Scholar
  103. Stacey, B. R., Barett, J. A., Whalen, E., et al. (2008). Pregabalin for postherpetic neuralgia: Placebo controlled trial of fixed and flexible dosage regimens on allodynia and time to onset of pain relief. The Journal of Pain, 9, 1006–1017.PubMedCrossRefGoogle Scholar
  104. Temple, A. R., Lynch, J. M., Vena, J., et al. (2007). Aminotransferase activities in healthy subjects receiving three-day dosing of 4, 6, or 8 grams per day of acetaminophen. Clinical Toxicology (Philadelphia), 45, 36–44.CrossRefGoogle Scholar
  105. Tofferi, J. K., Jackson, J. L., & O’Malley, P. G. (2004). Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis and Rheumatism, 51, 9–13.PubMedCrossRefGoogle Scholar
  106. Towheed, T. E. (2006). Pennsaid therapy for osteoarthritis of the knee: A systematic review and metaanalysis of randomized controlled trials. The Journal of Rheumatology, 33, 567–573.PubMedGoogle Scholar
  107. Towheed, T. E., Maxwell, L., Judd, M. G., et al. (2006). Acetaminophen for osteoarthritis. Cochrane Database Systemic Reviews, (1), CD004257.Google Scholar
  108. Tramer, M. R., Moore, R. A., Reynolds, D. J., et al. (2000). Quantitative estimation of rare adverse events which follow a biological progression: A new model applied to chronic NSAID use. Pain, 85, 169e82.CrossRefGoogle Scholar
  109. Vandevenne, M., Vandenbussche, H., & Verstraete, A. (2000). Detection time of drugs of abuse in urine. Acta Clinica Belgica, 55, 323–333.PubMedCrossRefGoogle Scholar
  110. Velly, A. M., Chen, H., Ferreira, J. R., & Friction, J. R. (2013). Temporomandibular disorders and fibromyalgia. In R. J. Moore (Ed.), Handbook of pain and palliative care: Biobehavioral approaches for the life course. New York: Springer.Google Scholar
  111. Wade, W. E., & Spruill, W. J. (2009). Tapentadol hydrochloride: A centrally acting oral analgesic. Clinical Therapeutics, 31, 2804–2818.PubMedCrossRefGoogle Scholar
  112. Watkins, P. B., Kaplowitz, N., Slattery, J. T., et al. (2006). Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial. Journal of American Medical Association, 296, 87–93.CrossRefGoogle Scholar
  113. Webster, L. R., Malan, T. P., Tuchman, M. M., et al. (2010). A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. The Journal of Pain, 11, 972–982.PubMedCrossRefGoogle Scholar
  114. Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Medicine, 6, 432–442.CrossRefGoogle Scholar
  115. Wiffen, P. J., McQuay, H. J., Edwards, J. E., et al. (2005). Gabapentin for acute and chronic pain. Cochrane Database Systemic Reviews, 20(3), CD005452.Google Scholar
  116. World Health Organization. (2000). Achieving balance in national opioids control policy: Guidelines for assessment. Geneva: WHO.Google Scholar
  117. Wu, J., Ginsberg, J. S., & Diamantidis, C. J. (2015). Chronic pain and analgesic use in CKD: Implications for patient safety. Clin J Am Soc Nephrol, 10, 435–442.PubMedPubMedCentralCrossRefGoogle Scholar
  118. Xiao, L., Mackey, S., Hui, H., et al. (2010). Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Medicine, 11, 1827–1833.PubMedCrossRefGoogle Scholar
  119. Zacny, J., Bigelow, G., Compton, P., et al. (2003). College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug and Alcohol Dependence, 69, 215–232.PubMedCrossRefGoogle Scholar
  120. Zhang, W., Doherty, M., Arden, N., et al. (2005). EULAR evidence based recommendations for the management of hip osteoarthritis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases, 64, 669e81.CrossRefGoogle Scholar
  121. Zhang, W., Moskowitz, R. W., Nuki, G., et al. (2007). OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis and Cartilage, 15, 981e1000.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sukdeb Datta
    • 1
  • Laxmaiah Manchikanti
    • 2
  1. 1.Datta Endoscopic Back Surgery and Pain CenterNew YorkUSA
  2. 2.Pain Management Center of Paducah, Anesthesiology and Perioperative MedicineUniversity of LouisvillePaducahUSA

Personalised recommendations